Form 4: Perrigo Executive Roberto Khoury Receives RSU Grant

Perrigo Company plc EVP Roberto Khoury was granted 42,142 restricted stock units vesting over three years.

Summary

• Roberto Khoury, EVP and President of CSCI at Perrigo Company plc, received a grant of 42,142 restricted stock units (RSUs).
• Each RSU represents a contingent right to receive one ordinary share of Perrigo Company plc.
• The RSUs are scheduled to vest in three equal annual installments beginning on May 13, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding executive compensation, which is neutral in terms of immediate market impact.

Positives

• The grant aligns executive compensation with long-term shareholder value through a multi-year vesting schedule.

Negatives

• The issuance of new RSUs results in potential future dilution for existing shareholders upon vesting.

Risks

• Future share price volatility may impact the ultimate value realized by the executive upon vesting.

Future Outlook

The RSUs will vest in three equal annual installments starting May 13, 2027, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity-based compensation for senior executives is standard practice in the pharmaceutical and consumer health sectors to ensure leadership retention and alignment with corporate performance goals.

Comparison to Industry Standards

• The use of three-year vesting schedules for equity grants is consistent with standard corporate governance practices for large-cap pharmaceutical companies.
• The grant size is commensurate with the responsibilities of an EVP-level role within a company of Perrigo's market capitalization.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual vesting and settlement of these units.

Next Steps

• Vesting of the first tranche of RSUs on May 13, 2027.

Key Dates

Keywords

Perrigo, PRGO, Form 4, Insider Trading, Executive Compensation, Restricted Stock Units